In this podcast, Hilary Baldwin, MD, FAAD, and Jeffrey Fromowitz, MD, FAAD, discuss the burden of rosacea, management tips, available treatments, antibiotic stewardship, and more.

Managing Papulopustular Rosacea

Learn more about what treatments are on the rise for plaque psoriasis, the latest management advice and what trends are shaping the future of the disease. 

The changing treatment landscape of plaque psoriasis

Given the population growth among Asian Americans, dermatologists in the United States likely will be treating more patients from this diverse cultural community. Ensuring positive outcomes starts with understanding the differences in which skin conditions most commonly affect these patients and what that means for treatment regimens, according to an expert panel presentation at the American Academy of Dermatology Virtual Meeting Experience (AAD VMX) 2021, held in April.

Asian Americans were the fastest-growing sector among all racial and ethnic groups in the United States between 2000 and 2019. The US Asian population grew 81% during that time, from approximately 10.5 million to a record 18.9 million. By 2060, the number of Asian Americans in the US is projected to surpass 46 million, according to the Pew Research Center.

Learning to differentiate common and uncommon conditions is key to serving this expanding patient market, said AAD VMX session speaker Hye Jin Chung, MD, MMSc, assistant professor at Harvard Medical School and director of the Asian Skin Clinic at Beth Israel Deaconess Medical Center in Boston, Massachusetts. (Table 1

She outlined the 4 inflammatory disorders predominately found in Asian patients—prurigo pigmentosa, cutaneous plasmacytosis, Kikuchi-Fujimoto disease (also known as histiocytic necrotizing lymphadenitis), and lipodystrophia centrifugalis abdominalis infantilis—and offered strategies on how to optimize treatments for these patients.

Prurigo pigmentosa presents as recurrent, pruritic, erythematous papules with reticular pigmentation. “The main differential diagnosis for pruritic papules on the trunk of young people would be pityrosporum folliculitis,” she said. “But in pityrosporum folliculitis, the papules are all follicular centric and you do not see reticular postinflammatory hyperpigmentation.”

The early stage of prurigo pigmentosa is characterized by a superficial perivascular infiltrate of neutrophils, whereas spongiosis and necrotic keratinocytes often appear in later stages.

 “A definitive mechanism of pathogenesis has yet to be determined,” Chung said. “But its relationship with ketosis has been well documented. Prurigo pigmentosa is associated with anorexia nervosa, diabetes mellitus, strict ketogenic diet, and bariatric surgery.”

The “keto rash” has been reported in those on the ketogenic diet, which includes consuming high amount of fats and low amounts of carbohydrates. The new entity known as keto rash is actually prurigo pigmentosa, according to Chung, and now dermatologists are seeing patients with prurigo pigmentosa from other racial backgrounds.

“Prurigo pigmentosa is easy to treat with doxycycline or minocycline,” Chung said. “Topical steroids and antihistamines do not work.” Cases of prurigo pigmentosa linked to the ketogenic diet may resolve without medical intervention if patients increase their carbohydrate intake, she noted.

Chung presented a case of a 68-year-old Vietnamese man with a rash on his trunk for more than 30 years. It began as pruritic but became asymptomatic. A punch biopsy on his back revealed dense perivascular and interstitial inflammation in the upper and middle dermis.

He received a diagnosis of cutaneous plasmacytosis, a benign proliferation of mature plasma cells. The pathogenesis is unknown, and it is common in middle-aged Asian individuals, she said.

Cutaneous plasmacytosis presents as skin lesions on the trunk, face, nape of the neck, and axilla as brown and red to purple-colored nonscaly patches, according to Chung.

There have been recent case reports of partial improvement with PUVA, a combination treatment consisting of prescribing the parent compound psoralen (P) and then exposing the skin to long-wave ultraviolet light (UVA) or excimer laser. Steroid injections, oral doxycycline, thalidomide, and chemoradiation have been used with little success, she added.

“Cutaneous plasmacytosis runs a chronic, largely benign course,” Chung said, noting that rare cases of cutaneous plasmacytosis have developed systemic involvement and clinicians should follow patients for malignancies and more. 

Kikuchi-Fujimoto disease presents with lymphadenopathy, fever, and erythematous macules with small central crusting on the head and neck. It is a rare benign condition that mimics tuberculosis lymphadenitis or lymphoma. 

“Patients are generally younger than 40 years of age with female predominance. It is mainly described in Asia but also reported in America, Africa, and Europe,” Chung said.

Skin manifestation, or skin rash, has been reported in 10% to 40% of patients with Kikuchi-Fujimoto disease, she said. Signs and symptoms usually resolve within 1 to 4 months. Chung said dermatologists can treat these patients with more supportive measures, including analgesics, antipyretics, and rest. In more severe cases, she recommended that dermatologists consider short-course oral corticosteroids and/or hydroxychloroquine.

Although it is usually a self-remedying disease, it may recur in 3% to 4% of cases. Patients with Kikuchi-Fujimoto disease should be carefully monitored for development of systemic lupus erythematous, which has been associated with Kikuchi-Fujimoto, Chung advised.

Lipodystrophia Centrifugalis Abdominalis Infantilis 

Authors of a statistical analysis of 168 cases of lipodystrophia centrifugalis abdominalis infantilis found that 160 were from Japan, South Korea, and China. The male-to-female ratio of cases was 1:1.6, and 80% of cases were on the groin, lumbar area, buttocks, or thighs.

More than 90% of patients present by age 5, and mechanical irritation is the cause in only 10% of cases, according to Chung.

Although the lesions progress slowly over several years, Chung said spontaneous resolution has been observed in more than 50% of patients by the time they reach their teens.

“Topical tacrolimus and pimecrolimus have been reported to prevent enlargement of lesions,” she said. Chung added that chloroquine, penicillin, vitamin E, and ibuprofen, as well as topical therapies such as corticosteroids or vitamin A, can help treat the condition.

Differentiating Melanonychia from Nail Unit Melanoma

Treating Asian patients also requires in-depth knowledge of the differences in how skin disorders present. Mi Ryung Roh, MD, PhD, associate professor of dermatology at Yonsei University College of Medicine and head of dermatologic surgery at Gangnam Severance Hospital in Seoul, South Korea, detailed how to differentiate melanonychia, a common disorder in the Asian population, from nail unit melanoma.

“Longitudinal melanonychia is a longitudinally oriented brown-black band that extends from the matrix to the distal portion of the nail plate. It accounts for nearly half of the cases of chromonychia,” she said. “The most common cause of melanonychia in all morphologies is subungual hemorrhage, followed by nail matrix nevus and trauma.”

Nail unit melanoma, or subungual melanoma, is rare in Western countries, with a prevalence of 0.7% to 3.5% of all melanoma cases. In South Korea, Japan, and China, the prevalence is 10% to 25% of all melanoma cases. Peak incidence is in the fifth to seventh decade of age but can be diagnosed at a younger age. Thumb and great toe are common sites. Longitudinal melanonychia is the first manifestation in 38% to 76% of cases.

Nail matrix biopsy is the recognized standard for diagnosing nail unit melanoma, but clinicians should consider biopsy-caused nail scarring and deformity, according to Roh. 

Dermoscopic features favoring nail unit melanoma in longitudinal melanonychia include having a bandwidth percentage higher than 40% to 65%, multicolor features, granular pigmentation, subungual hyperkeratosis, and micro-Hutchinson sign.

Longitudinal melanonychia caused by melanocytic activation commonly occurs in skin phototypes IV, V, and VI. Inflammatory disorders, including psoriasis, can activate longitudinal melanonychia, as can systemic disorders such as Addison disease. Trauma is also a common cause of melanocytic activation that causes longitudinal melanonychia, Roh said. 

Iatrogenic factors, such as chemotherapeutic and other drugs, can cause melanonychia. Other causes include nutritional deficiency such as vitamin D deficiency, Roh said.

“Melanonychia is a challenging symptom for clinicians irrespective of the patient’s age,” she said. “With careful history, clinical examination, and dermoscopy it is possible to determine whether it is benign or malignant. In suspected cases, nail matrix biopsy must be performed [because] tissue diagnosis remains the gold standard for diagnosis.”

Diagnosing and Treating Common Facial Pigmentary Disorders 

The 5 most common pigmentary concerns among Asian Americans are solar lentigines, melasma, acquired bilateral nevus of Ota-like macules, nevus of Ota, and postinflammatory hyperpigmentation, according to Woraphong Manuskiatti, MD, professor of dermatology at Siriraj Skin Laser Center at Mahidol University in Bangkok, Thailand. 

Manuskiatti, who presented on common facial pigmentary disorders in Asians and their treatment at the virtual AAD meeting, said making the right diagnosis is the most important first step.

“Solar lentigines present with multiple brown macules, mostly scattered all over the face,” he said.

Although acquired bilateral nevus of Ota-like macules, or Hori’s nevus, is a similar condition to nevus of Ota, there are important differences. Average age of onset is 30, or between 6 and 54 years, for Hori’s nevus, whereas nevus of Ota is congenital. Hori’s nevus has a bilateral distribution vs a predominately unilateral distribution in nevus of Ota. There is no mucosal involvement in Hori’s nevus but there is in nevus of Ota. 

Hori’s nevus histology features melanocytes in papillary and middle dermis versus melanocytes in papillary and reticular dermis for nevus of Ota. Hori’s nevus is less likely than nevus of Ota to respond to laser treatment, and the incidence of postinflammatory pigmentation is from 50% to 75% with Hori’s nevus compared with 10% in nevus of Ota, according to Manuskiatti (Table 3).

Melasma, another common pigmentary disorder in Asia, presents as brown pigment distributed symmetrically around the face, usually on the forehead, bilateral cheeks, upper lid, chin, or nasal bridge. 

Treatments vary according to the condition. For example, solar lentigines, acquired bilateral nevus of Ota-like macules (ABNOM or Hori’s nevus) and nevus of Ota can be treated with lasers. Melasma treatment usually begins with topicals, then chemical peeling and oral treatment, with lasers as an adjunct when needed. Postinflammatory hyperpigmentation is treated topically with oral therapy and laser as needed, according to Manuskiatti.

Manuskiatti presented a case of solar lentigines treated singularly with the Q-switched 532 nm Nd:YAG laser. Within 1 month, the patient was close to 100% improved. He also presented a patient with acquired bilateral nevus of Ota-like macules successfully treated 10 times with the Q-switched 1064 nm Nd:YAG laser, as well as a case of nevus of Ota 3 months after the eighth treatment with the 755 nm picosecond laser. 

However, “melasma is still a headache for us,” he said. 

First-line treatment for melasma includes tyrosinase inhibitors, hydroquinone, azelaic acid, kojic acid, arbutin, and licorice extracts. “Hydroquinone remains the most effective topical treatment for melasma, but no matter how effective it is a topical treatment alone does not produce impressive results in treating melasma,” Manuskiatti said. Studies have found that lasers should not be used as a first-line treatment for melasma but can be used as an adjunct in resistant cases.

Manuskiatti said when he does use a laser to treat melasma, it is a low-fluence Er:YAG laser or 755-nm picosecond laser.

Authors of a retrospective study of 561 Asian patients with melasma treated for 4 months with oral tranexamic acid found nearly 90% improved, 10% did not improve, and 0.4% worsened. But the melasma often recurs after stopping the medication. In this study, 27.2% relapsed in a median 7 months.

“Tranexamic acid may the game changer for treating melasma,” he said.

When treating postinflammatory hyperpigmentation, Manuskiatti starts with topical treatment.

“We also found the use of oral tranexamic acid is quite effective for treating postinflammatory hyperpigmentation. Pico toning [with the 755-nm picosecond laser] can be useful for treating laser-induced postinflammatory hyperpigmentation,” he said.

Chung, Manuskiatti and Roh reported no relevant or financial disclosures.

1. Chung HJ, Roh MR, Manuskiatti W. Skin Conditions in Asian patients that you do not want to miss: inflammatory diseases-1. Presented at: American Academy of Dermatology VMX; April 23-25, 2021; virtual.

2. U.S. Asian population grew fastest of any race, ethnicity in 2000-2019. Pew Research. Press release. April 9, 2021. Accessed May 6, 2021. 

U.S. Asian population grew fastest of any race, ethnicity in 2000-2019 | Pew Research Center

3. Beutler BD, Cohen PR, Lee RA. Prurigo pigmentosa: literature review. Am J Clin Dermatol. 2015;16(6):533-543. doi:10.1007/s40257-015-0154-4

4. Imamura S. Lipodystrophia centrifugalis abdominalis infantilis: statistical analysis of 168 cases. Pediatr Dermatol. 2012;29(4):437-441. doi:10.1111/j.1525-1470.2011.01584

5. Roh MR. Melanonychia vs nail unit melanoma. Presented at: American Academy of Dermatology VMX; April 23-25, 2021; virtual.

6. Singal A, Bisherwal K. Melanonychia: etiology, diagnosis, and treatment. Indian Dermatol Online J. 2020;11(1):1-11. doi:10.4103/idoj.IDOJ_167_19

7. Ko D, Oromendia C, Scher R, Lipner SR. Retrospective single-center study evaluating clinical and dermoscopic features of longitudinal melanonychia, ABCDEF criteria, and risk of malignancy. J Am Acad Dermatol. 2019;80(5):1272-1283. doi:10.1016/j.jaad.2018.08.033

8. Kungvalpivat P, Rojhirunsakool S, Chayavichitsilp P, Suchonwanit P, Wichayachakorn CT, Rutnin S. Clinical and onychoscopic features of benign and malignant conditions in longitudinal melanonychia in the Thai population: a comparative analysis. Clin Cosmet Investig Dermatol. 2020;13:857-865. doi:10.2147/CCID.S283112

9. Manuskiatti W. Common facial pigmentary disorders in Asians and their management. Presented at: American Academy of Dermatology VMX; April 23-25, 2021; virtual.

10. Sarkar R, Aurangabadkar S, Salim T, et al. Lasers in melasma: a review with consensus recommendations by Indian Pigmentary Expert Group. Indian J Dermatol. 2017;62(6):585-590. doi:10.4103/ijd.IJD_488_17

11. Lee HC, Thng TGS, Goh CL. Oral tranexamic acid (TA) in the treatment of melasma: a retrospective analysis. J Am Acad Dermatol. 2016;75(2):385-392. doi:10.1016/j.jaad.2016.03.001

Articles

Experts present detailed guidelines on how to diagnose and treat common skin diseases and conditions in the Asian American population. 

Treating Skin Conditions in Asian Patients 

The FDA has set a Prescription Drug User Fee Act (PDUFA) action date of March 31, 2022, for LetibotulinumtoxinA (Botulax; Hugel America, Inc), a joint venture between Hugel America, Inc. and Croma-Pharma GmbH, as a neurotoxin to treat moderate to severe glabellar (frown) lines in adult patients. The Biologics License Application (BLA) was accepted for review on June 15, 2021. 

Hugel initiated a 2015 study program (NCT01791920) support of LetibotulinumtoxinA and submitted the BLA on March 31, 2021. 

"The FDA's acceptance of our BLA is an important milestone for Hugel as it brings us one step closer to our goal of becoming a top aesthetics brand in the US by delivering high quality beauty solutions that are accessible and attainable," said James Hartman, president of Hugel America. "The groundwork has been done in the botulinum toxin category, but there's still plenty of opportunity for growth. We believe the market can continue to evolve and we look forward to participating in that evolution." 

Currently, letibotulinumtoxinA is available in 28 countries and has been a leader in the South Korean market for 5 years straight, according to the release. 

Hugel America is also trying to expand into Canada, Australia, and New Zealand.

1. Inc HA. Hugel America, Inc. announces U.S. FDA acceptance of biologics license application (BLA) for letibotulinumtoxinA for injection to treat glabellar (frown) lines. Cision PR Newswire. Press Release. June 15, 2021. Accessed June 17, 2021. 

https://www.prnewswire.com/news-releases/hugel-america-inc-announces-us-fda-acceptance-of-biologics-license-application-bla-for-letibotulinumtoxina-for-injection-to-treat-glabellar-frown-lines-301312900.html

Hugel America announces the FDA has approved the BLA application for letibotulinumtoxinA as a treatment for glabellar lines in adult patients.

PDUFA Date Set for LetibotulinumtoxinA

The FDA has approved StrataGraft (allogeneic cultured keratinocytes and dermal fibroblasts in marine collagen – dsat; Mallinckrodt) for the treatment of thermal burns containing intact dermal elements for which surgical intervention is clinically indicated (deep partial-thickness burns) in adults.

This approval makes StrataGraft the first approved donor site-free substitute to autograft for deep partial-thickness burns. StrataGraft is designed to handle like an autograft and promote the body’s healing process to achieve definitive closure of a majority of treated wounds, according to a press release.

While autografting is effective in providing closure of the original wound in patients with deep partial-thickness burns, it can lead to donor site complications, including pain, itching, increased risk of infection, and scarring," said Tracee Short, MD, burn surgeon and burn unit medical director at the Regional Burn Center at Baton Rouge General, Baton Rouge, Louisiana. "The approval of StrataGraft represents an important advancement in the treatment of patients with deep partial-thickness burns. Burn surgeons will now have a new biologic treatment to eliminate or reduce the need for autografting.

The approval is backed by positive data from a phase 3 clinical trial, STRATA2016 (NCT03005106), investigating a single application of StrataGraft in patients with acute thermal burns containing intact dermal elements involving 3-37% of the total body surface area (BSA). 

Results demonstrated significantly smaller area of burn wounds treated with StrataGraft required autografting by 3 months vs the area of burn wounds treated exclusively with autograft (p < .0001), according to the release.

Of the 71 StrataGraft-treated burn sites across all participants, 68 (96%) did not require autografting. Also, researchers found the difference in the percent area of StrataGraft and control autograft treatment sites that required autografting by 3 months was 98% (p < .0001). Patients who achieved durable closure of the StrataGraft treatment site at 3 months without autograft placement was 83% (95% CI: 74, 92). Additionally, patients who achieved durable closure of the autograft control treatment site at 3 months without additional autograft placement was 86% (95% CI: 78, 94).

The safety profile of StrataGraft consisted of erythema, swelling, local warmth and wound site infections, and was comparable to autografting in clinical studies. The most common (>2%) adverse reactions (AEs) were pruritus, blisters, hypertrophic scarring, and impaired healing. Also, there were no reports of rejection to StrataGraft and no patients discontinued due to adverse reactions.

"Today's FDA approval of StrataGraft marks a significant milestone for the burn care community and underscores our unwavering commitment and ability to bring paradigm-changing treatment options to patients with severe and critical conditions," said Steven Romano, MD, executive vice president and chief scientific officer at Mallinckrodt. "We are deeply appreciative of the patients who participated in the StrataGraft clinical trials, the physicians and study investigators involved in the clinical development program, and our employees, who have worked tirelessly over the last 20 years to help us bring StrataGraft to burn surgeons and the patients they treat." 

Mallinckrodt plans on evaluating StrataGraft in pediatric populations and in adults with full-thickness burns (third-degree burns).

1. plc M. Mallinckrodt announces u. S. Fda approval of stratagraft (Allogeneic cultured keratinocytes and dermal fibroblasts in murine collagen - dsat). Accessed June 16, 2021. https://www.prnewswire.com/news-releases/mallinckrodt-announces-us-fda-approval-of-stratagraft-allogeneic-cultured-keratinocytes-and-dermal-fibroblasts-in-murine-collagen---dsat-301313193.html

Mallinckrodt announces the FDA approval of StrataGraft (allogeneic cultured keratinocytes and dermal fibroblasts in murine collagen – dsat) for the treatment of adults with thermal burns.

StrataGraft Approved for Thermal Burns in Adults

Podcasts

This episode dives into how health care policy impacts gender and sexual minority patients, including exploring the Affordable Care Act (ACA) and Medicaid expansion, and identifying state and federal nondiscrimination protections that help defend equal access to health care for this patient population. 

The Cutaneous Connection: Episode 25- How Health Care Policy Impacts Gender and Sexual Minority Patients

Nutrafol announced today the release of a new nutraceutical targeting postpartum hair loss in women.

The new addition to their product is called Nutrafol Postpartum and it is an OBGYN-developed postpartum hair nutraceutical, according to a press release announcing the supplement.

Nutrafol Postpartum’s goal is to help women who experience postpartum hair loss grow thicker and fuller hair. This is achieved by helping the body recover from multiple stresses, like childbirth and motherhood, while also filling any gaps in nutrition with natural ingredients. 

Around 50% of women experience postpartum hair thinning and shedding starting at about 3 months post-birth and can last up to 6 months, according to the release. The hair does return, but it can lack thickness and, in some cases, grow in thinner due to the hair growth cycle returning to its pre-pregnancy state. The hair growth cycle resets after about 6 to 15 months. 

“Women can begin using Nutrafol Postpartum immediately after childbirth through their first year postpartum. We recommend taking the product for 3-6 months and beyond to support recovery and replenish the body to promote better hair growth,” Anne Kennard, DO, FACOG, Dipl-ABLM, a board-certified obstetrician gynecologist, San Luis Obispo, California, told 

®. “If patients are still breastfeeding after the first year, we recommend continuing with Nutrafol Postpartum. Once they’ve stopped breastfeeding, they can switch to Nutrafol Women.”

Kennard helped develop Nutrafol Postpartum because of her experience as both an OBGYN and a mother. There were not products targeting the root causes of hair thinning until this point, she says, and after giving birth, women can be very cautious about what ingredients they put into their bodies. 

Product ingredients include nettle, pea sprouts, shatavarti, and Omega3s. The ingredients are from whole-food sources and provide nutritional support within the Recommended Dietary Allowances (RDA) and Tolerable Upper Intake Level (UL) values set by the FDA with no ingredients found to be contraindicated in breastfeeding and is compatible with most prenatal vitamins and multivitamins, according to Kennard. 

“Postpartum hair shedding is so common,” Kennard says. “According to the American College of Obstetrics and Gynecology, most women experience it. Remind your patients that they are not alone, and there is now a natural way to support their hair growth recovery with clinically-tested, breastfeeding-friendly ingredients.” 

Kennard helped develop Nutrafol Postpartum.

Leff L. Sneak peak of new launch from Nutrafol. Published online June 15, 2021. Accessed June 15, 2021. https://www.prnewswire.com/news-releases/nutrafol-drives-hair-health-innovation-with-new-postpartum-supplement-301313177.html

Nutrafol launches a new nutraceutical, called Postpartum, aimed at helping women’s hair health post-pregnancy. 

Nutrafol Launches Postpartum Nutraceutical

A study found WaterWipes, a plant-based baby wipe comprised of 99.9% water and a drop of fruit extract, helped reduce facial pressure injuries (FPI) caused by prolonged wear of personal protective equipment (PPE).

When asked about the need for this study, Jill Sommerville, MSc, director of medical at WaterWipes, said, “During the early part of the COVID-19 pandemic, facial pressure ulcers (FPUs) were a significant problem to Intensive Care Unit (ICU) health care staff throughout the world, resulting from wearing protective face masks for prolonged periods."

She continued, “There were instances where masks mechanically indented the skin, causing redness, blisters, and skin tears. When a break in the skin occurs, it becomes a portal for pathogens, placing staff at a significant risk of infection, including COVID-19 itself, and when infected, staff have had to leave the ICU for quarantining and treatment. Hospitals noticed that they were losing vital ICU staff from their rosters due to open facial wounds and this needed to be prevented as quickly and safely as possible.”

The study was conducted by 300 frontline health care professionals (HCPs) from the Royal College of Surgeons in Ireland (RCSI), who also commissioned the study.

Participants from the COVID-19 wards, ICU, and emergency department were given a product bundle consisting of WaterWipes baby wipes, medical tape, and moisturizer. The HCPs were instructed to cleanse their face with the wipes, then apply the moisturizer once the skin was clean and dry. Tape was then cut to size and placed directly on the bridge of the nose and cheekbones prior to wearing PPE.

The 5 steps to using the product bundle included:

Skin protection, using cleansing and moisturization.

Selection of a face mask appropriate to the level of care to be provided.

Material use, application of tape and face mask.

Skin and face mask inspection during the clinical shift as appropriate.

Skin inspection, cleansing and hydration on removal of the PPE and tape.

From March to May 2020, results showed that prior to using WaterWipes, 29% (n=33) of participants developed a FPI from PPE. However, when the HCPs used the product bundle, they were 5 times less likely to develop a FPI while wearing PPE, with 8% (n=9) developing an FPI.

“This means that staff who followed the practical 5-step solution of cleaning and moisturizing routinely before and after use of their PPE, were almost five times less likely to develop an FPI,” Sommerville said. “This offers a level of comfort and protection to frontline ICU staff, improving their quality of life and enabling these important staff to continue, unhindered, with providing excellent patient care.”

She added, “Going forward, the study tells us that if skincare is prioritized, and a systematic preventative care bundle approach is adopted, there are clear benefits for the frontline workers and the workplaces involved. HCPs who follow the step process will have reduced chances of developing facial pressure injuries.”

A study found WaterWipes, a plant-based baby wipe comprised of 99.9% water and a drop of fruit extract, helped reduce facial pressure injuries (FPI) caused by prolonged wear of personal protective equipment (PPE).


Study: WaterWipes Reduces Facial Pressure from PPE

Poll

POLL: What is your go-to treatment for vitiligo?

A glimpse at what to expect from Dermatology Times this week.

 What’s New on Dermatology Times: June 21-25

POLL: Do you treat the entire field of a patient diagnosed with actinic keratosis?

What’s New in Acne and Rosacea for 2021?

Emmy Graber, MD, presented the updates in acne and rosacea treatments at the SCALE Acne and Rosacea update on June 9, 2021.

Molluscum Contagiosum Treatment Demonstrates Success in Phase 3 Trial

The B-SIMPLE4 phase 3 trial achieved positive efficacy results for the treatment of molluscum contagiosum.

COVID-19 Increases Urgency of Addressing Vitamin D Deficiencies in Patients With Skin of Color

A higher prevalence of vitamin D deficiency in people of color may be contributing to a higher burden of COVID-19 in minority populations. Dermatologists are encouraged to address vitamin D status in patients and recommend supplementation, which might have other health benefits.

Dangers, Benefits of Biologics Must Be Carefully Weighed

Biologic therapy has proven very useful in treating an increasing number of dermatologic diseases and conditions. However, caution is warranted for patients with chronic infectious diseases.

Tips for Maintaining Mental Health as a Gender and Sexual Minority

Klint Peebles, MD, FAAD, co-chair of the AAD LGBTQ/GSM Expert Resource Group, tips and resources for maintaining your mental health as a gender and sexual minority.

AAD Tackles Tough Issues in Upcoming Acne Update

American Academy of Dermatology’s updated guidelines on acne will cover dermatology’s hottest issues, from dosing and monitoring established medications to exploring new antibiotics and addressing antibiotic stewardship.

IDP-126 Meets Endpoints in Second Phase 3 Study

IDP-126, an acne vulgaris treatment for patients ages 9 and older, met all of its endpoints in a 12-week phase 3 study.

Nutrafol launches a new nutraceutical, called Postpartum, aimed at helping women’s hair health post-pregnancy.

This episode dives into how health care policy impacts gender and sexual minority patients, including exploring the Affordable Care Act (ACA) and Medicaid expansion, and identifying state and federal nondiscrimination protections that help defend equal access to health care for this patient population.

Treating Skin Conditions in Asian Patients

Experts present detailed guidelines on how to diagnose and treat common skin diseases and conditions in the Asian American population.

ICYMI, some of this week’s featured content includes a new podcast episode, as well as articles on treating skin conditions in Asian patients, the newest FDFA approvals, acne treatment updates from AAD, and more.

Weekly Roundup: 14-18

 explains psychodermatology, how to properly remove a skin tag, and how much sunscreen you should apply every day. Also, 

reveals how to manage keratosis pilaris during the summer months and 

provides tips on how to treat a sunburn quickly. Finally, 

s investigates if pore strips are really bad for our skin or not. 

Hold Up, Pore Strips Could Actually Be Really Bad For Your Skin

Have Dry, Bumpy Skin? Here’s How to Manage Keratosis Pilaris This Summer

What Makes You More Likely to Get Skin Tags and What to Do About Them

Should You Be Seeing a Psychodermatologist?

How Much Sunscreen Do You Really Need to Apply Every Day?